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Abstract
Background: A rapid in‑house TM4 mycobacteriophage‑based assay, to identify multidrug resistance against various anti‑tuberculosis drugs, using
the fast‑growing Mycobacterium smegmatis mc2 155 in a microtiter plate format was evaluated, based on phage viability assays. Methods: A variety
of parameters were optimized before the study including the minimum incubation time for the drugs, phage and M. smegmatis mc2 155 to be in
contact. An increase in phage numbers over 2 h was indicative that M. smegmatis mc2 155 is resistant to the drugs under investigation, however
when phage numbers remained static, M. smegmatis mc2 155 found to be sensitive to the drug. Results: The study confirmed that the data are
statistically significant and that M. smegmatis mc2 155 is, in fact, sensitive to isonazid, iifampicin, pyranzaimide, and ethambutol as phage
numbers doubled over 2 h (P = 0.015, 0.018, 0.014, and 0.020). The study also confirmed that M. smegmatis mc2 155 is resistant to the drugs
ampicillin, erythromycin, amoxicillin streptomycin as phage numbers remain static over the same 2 h period (P = 0.028, 0.052, 0.049, and 0.04).
This drug‑susceptibility profiling of eight different drugs against M. smegmatis mc2 155 was detected in as little as 1½ days with a cost of ~ one
euro and fifteen cent to test four drugs. Conclusion: This test is rapid to perform and will have widespread applications in drug‑susceptibility
testing of other members of the mycobacterial genus. In addition, the platform could also be used as a tool for high‑throughput screening of
novel antimycobacterial drugs. The main assets of this assay include its relatively cheap cost, versatility, and quick turnaround time.
Keywords: Drug susceptibility, mycobacteriophages, Mycobacterium smegmatis, optimization study

Introduction
The emergence of multi‑drug resistant (MDR) bacterial species
is a major concern in the modern world. Mycobacterial species,
in particular, have developed resistance to a large array of
antibiotics which disrupt cell wall biosynthesis. Their ability
to resist such antibiotics is caused by the structure of their cell
wall, which is composed of approximately 60% lipids making
them notoriously difficult to treat. Most mycobacteria are
susceptible to the antibiotics clarithromycin and rifamycin, but
several antibiotic‑resistant strains have emerged.[1]
The delay in identifying drug susceptible isolates is due to
the lack of advanced technology and the time involved in
sample preparation. Globally, most susceptible patients are
not diagnosed in time and do not receive appropriate therapy.[2]
They are clearly at risk of developing even more resistant
mycobacterial infections and transmitting these resistant
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mycobacterial strains. With today’s knowledge, available
diagnostic tools and epidemiological advances, it cannot be
considered acceptable to wait for 16 days to know if a clinical
isolate is drug susceptible or not. Thus, the traditional practices
of identification should be improved on. From the literature,
it has been noted that three established methods, in particular,
are used to identify drug susceptibilities in mycobacterial
species (minimum inhibitory concentrations [MICs],
BACTEC 460TB method, and the mycobacteria growth
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indicator tube [MGIT] 960 system).[3] The BACTEC and the
MGIT methods have been adopted by many laboratories in
the Western world and are based on the automated detection
of growth in a liquid medium with anti‑tuberculosis drugs.
These methods are, therefore, faster than those based on
visual detection of growth on solid medium. However, one
disadvantage of these systems is the inability to check the
colony morphology of the bacterial cultures. Both invisible
contamination and overgrowth with atypical mycobacteria
affect the reliability of the tests. In addition, these methods
have disadvantages in that they involve multiple tubes or
bottles and are restricted to discriminating between resistance
and susceptibility, rather than determining the exact MICs of
the drugs. The three methods mentioned above are, however,
reproducible, accurate, and relatively cheap. The materials used
in performing each test are cheap, although the sophisticated
equipment required for BACTEC and MGIT is relatively
expensive.
Laboratories in most developing countries lack this
sophisticated and costly equipment required to identify MDR
mycobacterial strains. The development of an assay which has
the potential to identify MDR‑mycobacterial species at a low
cost and rapid time would be highly beneficial. One potential
way to reduce the cost of drug‑susceptibility testing involves
the use of mycobacteriophages,[4] which have relatively rapid
replication rates (unlike the slow growth of their hosts), are
simple to use, and are relatively inexpensive to propagate.
Our study set out to prove the concept of this assay using a
fast‑growing surrogate strain (M. smegmatis mc2 155), which
would determine the viability of mycobacteria following
exposure to a range of commonly used drugs. Initially, critical
parameters were optimized, after which the efficacy of the
assay was evaluated using a blinded study. The principle is
based on the fact that the phage will only infect viable cells,
and the increase in their numbers over time is consistent with
the host strain demonstrating resistance to the drug under
investigation.

Methods
Preparation and standardization of Mycobacterium
smegmatis mc2 155

M. smegmatis mc2 155 (CIT culture collection) was utilized in
the study to optimize the assay as it is a fast‑growing strain and
nonpathogenic. Cultures of M. smegmatis mc2 155 (previously
stored at −80°C) were standardized using the DEN‑1
McFarland Densitometer (Grant‑bio) to achieve McFarland
Standards of 0.5 (approximately 1.5 × 108 cfu/ml) in log phase
and suspended in brain heart infusion (BHI) broth (Sigma
Aldrich). The mycobacterial cultures of M. smegmatis
mc2 155 were then transferred to sterile screw‑cap glass
tubes‑containing glass beads (5 mm) (Sigma Aldrich) (to
disrupt the cell wall) in 2 ml of BHI broth. Suspensions
were homogenized with a vortex mixer for 15–20 s. Large
clumps were allowed to settle by allowing the suspensions

to stand at room temperature for 10 min. The supernatants
were transferred to sterile tubes and adjusted to 101 CFU/ml,
102 CFU/ml, 103 CFU/ml, 104 CFU/ml, and 105 CFU/ml with
BHI broth (Sigma Aldrich) and standardized using the DEN‑1
McFarland Densitometer (Grant‑bio) to achieve McFarland
standards of 0.5 (1.5 × 108 cfu/ml).

Confirming the phenotype of Mycobacterium smegmatis
mc2 155 through growth profiling, purity streaks, and
Ziehl–Neelsen staining
A growth curve of M. smegmatis mc 2 155 and BHI
broth (Sigma Aldrich) was generated to standardize and
confirm the purity and identity of M. smegmatis mc2 155
using established methods.[5] Before the addition of the drug
and the mycobacteriophage TM4, M. smegmatis mc2 155 was
suspended in 5 ml of BHI broth (Sigma Aldrich) and 0.05%
Tween 80 (Sigma Aldrich) and incubated at 37°C for 12 h. The
cell suspensions following 12 h incubation were standardized
using the DEN‑1 McFarland Densitometer (Grant‑bio) to
achieve a McFarlands standard of 1 × 108 cfu/ml (McFarlands
standard 0.5).
Each cell suspension grown in broth was checked for purity
by performing the four‑streak method on BHI agar (Sigma
Aldrich) followed by incubation at 37°C for 48 h.
Ziehl–Neelsen staining was also performed as described
previously,[6] and visualized using the Olympus CH30 light
microscope (Olympus). A 2.5 µl volume of M. smegmatis
mc2 155 was added to 100 µl of fresh media (BHI broth) (Sigma
Aldrich) and 30 µl of 0.05% Tween 80 contained in three
separate wells of a sterile microtiter plate (Sarstedt, Germany).
The OD of the three wells was read at 600 nm using the
Mutiskan FC (Thermo Scientific) for 40 h at 37°C and average
absorbance readings of the three wells were calculated.

Preparation and standardization of the mycobacteriophage
TM4

To standardize phage propagation, 100 µl of a TM4
mycobacteriophage stock (Titer 8 × 10 8 PFU/ml) (CIT
culture collection) was added to 100 µL of early log phase
M. smegmatis mc2 155 cells (log phase was established
following repeated standard growth curve analysis) in 5 ml
of BHI broth (Sigma Aldrich) and incubated at 37°C for 48 h
previously established from other methods.[7] Subsequently
after 48 h, 2 ml of the culture was removed and placed in
a microfuge tube and centrifuged at room temperature at
2000 × g for 5 min to pellet cellular debris. This was then
filter‑sterilized using a 0.2 µm filter (Sarstedt, Nümbrecht,
Germany).
A volume of 100 µl of the filter sterilized supernatant was
added to 500 µL of early log phase M. smegmatis mc2 155
in a microfuge tube and incubated at 37°C for 30 min. The
suspension was then added to 5 ml of a BHI broth 0.75%
overlay agar tube tempered at 50°C and poured onto the surface
of a BHI agar plate. Plates were incubated at 37°C for 48 h
and then examined for plaques.
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Phage stocks were generated with the addition of 5 ml of phage
buffer (50 mM TRIS pH 8, 150 mM NaCl, 10 mM MgCl2, and
2 mM CaCl2) to the plate described in method 3.2.1. Sterile
hockey sticks were also aseptically run across the surface of
the agar plate to physically recover the phages. The plate was
then incubated for 2 h at 37°C with shaking. The buffer was
subsequently recovered from the plate, centrifuged to pellet
debris and filter‑sterilized using a 0.2 µm filter and stored at
4ºC until further use.

Each sterile microtiter plate was removed from the 37°C
incubator following its allocated time period. BHI (Sigma
Aldrich) agar plates were seeded with a 0.5 McFarland
standard of M. smegmatis mc2 155. A three microliter volume
of the drug from the appropriate microtiter plate was added
to the appropriate seeded agar plates. Plates were incubated at
37°C for 24 h and plates were subsequently examined for the
presence of zones of inhibition (mm) after each time according
to the CLSI guidelines.

Determination of the minimum inhibitory concentrations
of isonazid, rifampicin, ampicillin, pyranzamide,
erythromycin, ethambutol, amoxicillin, and streptomycin

Determination of the minimum exposure time for
Mycobacterium smegmatis mc 2 155, ampicillin/
rifampicin, and TM4 mycobacteriophage to be in contact

The MICs of each drug under investigation was performed to
establish whether the drug had an antimycobacterial effect and to
determine the drug concentration (if any) required to adequately
kill M. smegmatis mc2 155. The MICs of each drug (isonazid,
pyranzamide, ethambutol, and rifampicin) (Sigma Aldrich) were
determined as follows. An overnight culture of M. smegmatis
mc2 155 incubated at 37°C was prepared and standardized using
the DEN‑1 McFarland Densitometer (Grant‑bio) to reach a
McFarland standard of 0.5. A stock solution of the four drugs
was prepared. Some drugs such as rifampicin were resuspended
in methanol (16 mg/ml), pyranzamide was resuspended
in ethanol (5.7 mg/ml), and ethambutol and isonazid were
resuspended in sterile distilled water (50 mg/ml). Each stock
solution was stored at −20°C until needed.

Two‑fold dilutions of each drug under investigation were
prepared using the stock solutions as outlined above to achieve
final assay concentrations of 16 µg/ml, 8 µg/ml, 4 µg/ml,
2 µg/ml, 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, and 0 µg/ml. These
dilutions were added to an appropriate volume of log phase
M. smegmatis mc2 155 cells which was previously established
in section 2.2 (contained in BHI broth (Sigma Aldrich),
resulting in a cell density of 5 × 105 cfu/ml. The tubes were
incubated at 37°C for 24 h. The concentration of antimicrobial
in the first clear tube (no growth) after 24 h was indicative of
the MIC for each drug.[8]

Determination of the minimum exposure time for
Mycobacterium smegmatismc2 155 and the drugs under
investigation to be in contact
To prove the efficacy of the four drugs that have an effect on
M. smegmatis mc2 155 (proven by the MIC values) and the
other four drugs that do not have an effect on M. smegmatis
mc2 155, an optimization assay was conducted to determine
the minimum exposure time for the drug and M. smegmatis
mc2 155 to be in contact.

For isonazid (0.25 µg/ml), 100 µl of M. smegmatis mc
2 155 suspension (Neat, 101, 102, 103, 104, and 105 CFU/ml)
was placed in six allocated wells of five sterile microtiter
plates (Sarstedt, Germany) (one for each different temperature
was used). The first microtiter plate was tested directly after
the addition of the drug and bacteria (i.e., 0 h) (second plate:
2 h, third plate: 4 h, fourth plate: 6 h, and fifth plate: 8 h).
126

The first part of this procedure was conducted using the
optimized conditions as outlined in Section 2.5, utilizing
an incubation period of 2 h for M. smegmatis mc2 155 and
ampicillin and rifampicin in the microtiter plates.
Following the 2 h incubation period, 48 µl of mycobacteriophage
TM4 (Neat, 101, 102, 103, 104, and 105 PFU/ml) was added to
the six allocated wells of the sterile microtiter plates‑containing
ampicillin (2 µg/ml) (Sarstedt, Germany) for a specified time of
0, 30, 60, 90, and 120 min and incubated at 37°C to establish
the necessary time for the drug, the phage, and the bacteria to
be in contact. The ten sterile microtiter plates (10 plates for
rifampicin in duplicate) (plate one and six were incubated for
0 min, plate two and seven were incubated for 30 min, plate
three and eight were incubated for 60 min, plate four and nine
were incubated for 90, and plate five and ten were incubated
for 120 min) were removed from the 37°C incubator following
their allocated incubation periods and standard plaque assays
were performed to determine the effect on plaque numbers.
For ampicillin and rifampicin, phage numbers were determined
from the wells by adding 100 µL of the bacterial/drug/phage
suspension from separate wells to 100 µL of early log phase
M. smegmatis mc2 155 cells in a five microliter BHI 0.75% w/v
overlay agar tube which was tempered to 50°C. The overlay
was then poured onto the surface of a BHI agar plate (Sigma
Aldrich). Plates were incubated at 37°C overnight and
then examined for phage plaques. The same procedure was
performed for rifampicin.

Application of the optimized mycobacteriophage‑based
microtiter plate assay to identify drug susceptibilities of
six additional drugs

Following the optimization assays, the efficacy of six commonly
used drugs was evaluated (streptomycin, erythromycin,
ethambutol, pyranzaimide, amoxicillin, and isonazid). The same
procedure was performed as outlined in Section 2.5 and Section
2.6; however, the optimized time periods previously established
for the drug, the mycobacteriophage TM4 and M. smegmatis
mc2 155 were utilized (i.e., 2 h) throughout as outlined in Figure 1.

Evaluation of the efficacy of the mycobacteriophage‑based
drug‑susceptibility assay by undertaking a blinded study
Following the assay, a blinded study was conducted to ensure
that the results obtained were not affected by bias. For the
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Figure 1: The procedure involved in the development of a mycobacteriophage‑based drug‑susceptibility assay by incubating Mycobacterium smegmatis,
a drug under investigation and the mycobacteriophage TM4 to identify drug susceptibilities through plaque assays

blinded study the same eight drugs, isonazid, rifampicin,
ampicillin, pyranzamide, erythromycin, ethambutol,
amoxicillin, and streptomycin (Sigma Aldrich) were retested.
The drugs were randomly coded. The primary objective was
to identify drug susceptibilities of M. smegmatis255 to eight
randomized unknown drugs based on the formation of plaques.

Data analysis

Statistical analysis was performed with IBM SPSS Software
v. 24, (Armonk, NY, USA). To determine if the data were
statistically significant, the normality of the data was first
assessed with the Shapiro–Wilks test at a significance level of
0.05. A value of P < 0.05 was interpreted as indicating significant
correlation at a confidence interval of 95%. Nonparametric tests
were chosen for data not normally distributed.

Results
Phenotype of Mycobacterium smegmatis mc2 155 by
using growth profiling, purity streaks, and Ziehl–Neelsen
staining
Ziehl–Neelson staining, the culture appeared as red bacilli in
clusters under the × 100 objective lens as expected as outlined
in Figure 2a. Tween Eighty (0.05%) prevented clumping of M.

smegmatis mc2 155 throughout its growth and led to an efficient
growth curve. The doubling rate of M. smegmatis mc2 155 is
typically one to 2 h; therefore, readings were taken every hour to
observe this effect. Following 12 h of incubation M. smegmatis
mc2 155 entered its log phage for approximately 12 h until it
reached stationary phase at 24 h. Following. The cultures of the
M. smegmatis mc2 155 culture on BHI agar (Sigma Aldrich),
appeared as filamentous, irregulated, undulated margin,
flat in shape, and cream‑white in color indicating that pure
colonies were obtained when a purity streak was performed
as described previously[9] and as outlined in Figure 2b. The
presence of red bacilli following Ziehl–Neelsen staining and
the colony morphology described above confirms the identity
of M. smegmatis mc2 155. The growth rate of M. smegmatis
mc2 155 was measured spectrophotometrically at an OD of
600 nm as demonstrated in Figure 2c.

The determination of the minimum inhibitory concentrations
and determination of the minimum exposure time of
Mycobacterium smegmatis mc2 155 and the drugs under
investigation to be in contact
The MIC of each drug under investigation was determined
using M. smegmatis mc2 155 to record the concentration
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required to kill viable M. smegmatis mc2 155 cells and to
establish an effective drug concentration for the assay. The
four drugs in Table 1 exhibited growth‑inhibitory effects
against M. smegmatis mc2 155, although some drugs had a
better inhibitory effect than others. The MICs of each drug
varied as outlined in Table 1. The highest MIC obtained was
for ethambutol at 5 µg/ml, whereas the lowest MIC value
obtained was for isonazid at 0.25 µg/ml. The highest MIC
values (zones of inhibition cm) for each drug were obtained
after 2 h. From 4 to 8 h, the zones of inhibition began to
decrease.
Optimization assays were conducted according to the CLSI
guidelines to determine the minimum contact period for
M. smegmatis mc2 155, and the drug under investigation. All
eight drugs were analyzed for this optimization assay.
The optimization assay was undertaken to determine the
minimum contact time period for M. smegmatis mc2 155, and
the drug of choice (in this case the eight drugs were utilized).
The determination of the minimum contact time was based
on MIC values as outlined in Table 1. Comparison of contact
periods was determined over an 8 h time frame.

Table 1 provides an accurate determination of the contact time
required. It is evident that a contact time of 2 h is sufficient to
achieve an efficient response.

Determination of the minimum exposure time of
Mycobacterium smegmatis mc2 155, ampicillin/rifampicin
and TM4 mycobacteriophage to be in contact
Optimization assays were conducted to determine the optimum
contact period for M. smegmatis mc2 155, the drug and the
mycobacteriophage TM4. Ampicillin (2 µg/ml) (Sigma
Aldrich) and rifampicin (4 µg/ml) (Sigma Aldrich) were used
for the purpose of the optimization assays.

The optimization assay was undertaken at time intervals of
30 min in duplicate and was based on the changes in plaque
numbers (pfu/ml) as outlined in Figure 3. An increase in
phage numbers was seen to be indicative of drug resistance as
TM4 can lyse viable mycobacterial cells which have not been
inactivated by the drug.
For ampicillin (2 µg/ml) (Sigma Aldrich), at time zero,
the average plaque numbers obtained were 46 pfu/ml and
after 120 min, the average plaque numbers obtained were
152 pfu/ml. For rifampicin (4 µg/ml) (Sigma Aldrich), the
plaque numbers (pfu/ml) obtained at 0 min were 76 pfu/ml
and following 120 min the plaque numbers obtained were
76 pfu/ml.
M. smegmatis mc2 155 is resistant to ampicillin as outlined in
Figure 3 given the large increase in plaque numbers (pfu/ml)

a

b

c

Figure 2: (a) Ziehl Neelsen staining of Mycobacterium smegmatis
mc2 155 as described previously (Cappucino and Sherman, 2014) (b)
Purity streak of Mycobacterium smegmatis mc2 155 on brain heart
infusion agar (Sigma Aldrich) after incubation for 48 h at 37°C (c) Growth
curve of Mycobacterium smegmatis mc2 155 at OD600nm

Figure 3: Optimum time (minutes) required for ampicillin and
rifampicin under investigation to be in contact with Mycobacterium
smegmatis mc2 155 based on the change/no change in PFU/ml for the
mycobacteriophage TM4

Table 1: Minimum inhibitory concentrations and zones of inhibition (cm) of four drugs used to determine the minimum
contact time for Mycobacterium smegmatis mc2 155 and the drug under investigation to be in contact
Drug
Isonazid
Rifampicin
Pyrazinamide
Ethambutol

128

MIC
(μg/ml)

Zones of inhibition
(cm) after two hours

Zones of inhibition
(cm) after four hours

Zones of inhibition
(cm) after six hours

Zones of inhibition
(cm) after eight hours

0.25
2
0.5
5

1.3
2.6
1.6
2.9

1.1
2.4
1
2.7

1
1.9
0.9
2.3

0.7
1.9
0.9
2.2
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from time 0 min to time 120 min. Phage numbers (pfu/ml)
that remain static from time 0 to time 120 min suggest that
M. smegmatis mc2 155 is sensitive to the drug as the drug has
inactivated viable cells.
A graphical representation of the optimum time period for the
mycobacteriophage TM4, M. smegmatis mc2 155 and the drug
to be in contact was constructed. As outlined in Figure 3, the
average pfu/ml either increased with respect to time (minutes)
or remained static throughout the indicated time periods for
ampicillin and rifampicin according to their efficacy against
the host. A time period of 2 h was chosen based on Figure 3.

Application of the optimized mycobacteriophage‑based
microtiter plate assay to identify drug susceptibilities of
six drugs
To ensure consistency of results and to test the efficacy of the
optimized assay, various other drugs were used to indicate
drug susceptibilities. Each assay was performed in triplicate.

The drugs ampicillin (4 µg/ml) (Sigma Aldrich) and
rifampicin (2 µg/ml) (Sigma Aldrich) were tested for drug
susceptibilities as outlined in Figure 4. To allow for comparison
in identifying drug susceptibilities two time points (t = 0 h
and t = 2 h) were utilized based on the experiment above. As
already discussed, an increase in phage numbers is indicative
of drug resistance. From Figure 4 it can be said that M.
smegmatis mc2 155 is resistant to Ampicillin (P = 0.028) as a
result of the large increase in plaque numbers (pfu/ml) from
time 0 min to time 120 min. M. smegmatis mc2 155 appears
to be sensitive to rifampicin (Sigma Aldrich) (P = 0.018) as
phage numbers (pfu/ml) remain static from time 0 to time 4 h.
The drugs streptomycin (2.5 µg/ml) (Sigma Aldrich) and
isonazid (0.25 µg/ml) (Sigma Aldrich) were also tested against
M. smegmatis mc2 155 as outlined in Figure 4. Similarly, two
time points (t = 0 h and t = 4 h) were utilized to contrast the
difference in plaque numbers between the two points. As
already discussed, an increase in phage numbers is indicative of
drug resistance. From Figure 4, it can be said that M. smegmatis
mc2 155 is resistant to streptomycin (P = 0.049) as a result
of the large increase in plaque numbers (pfu/ml) from time
0 min and time 120 min. M. smegmatis mc2 155 appears to be

Figure 4: Drug‑susceptibility profiles of four drugs (streptomycin,
isoniazid, rifampicin and ampicillin) based on changes in average pfu/ml
of the mycobacteriophage TM4 versus time (hours T0–T2)

sensitive to isonazid (P = 0.015) as phage numbers (pfu/ml)
remain static from time 0 to time 120 min.
Pyranzamide (0.5 µg/ml) (Sigma Aldrich),
erythromycin (0.15 µg/ml) (Sigma Aldrich), ethambutol
(5 µg/ml) (Sigma Aldrich), and amoxicillin (4 µg/ml) (Sigma
Aldrich) were also used in this assay to demonstrate drug
susceptibilities based on differences in plaque numbers (pfu/ml)
as outlined in Figure 5. M. smegmatis mc2 155 appears to
be resistant to erythromycin (Sigma Aldrich) (P = 0.048)
and amoxicillin (Sigma Aldrich) (P = 0.049) as plaque
numbers (pfu/ml) obtained in Figure 5 increase from time 0
to time 4 h indicating that M. smegmatis mc2 155 is resistant
to the three drugs. M. smegmatis mc2 155 is sensitive to
the drugs Pyranzamide (Sigma Aldrich) (P = 0.014) and
Ethambutol (Sigma Aldrich) (P = 0.02) as indicated in
Figure 5. The plaque numbers (pfu/ml) from time 0 to time 4 h
remain relatively static indicating that the cells are still viable.
The data obtained in relation to the drug susceptibilities appears
to be statistically significant as P < 0.05 at a confidence interval
of 95% were obtained as outlined above.
Two‑time points (Time zero and Time 4 h) were utilized to assess
the drug susceptibility of four drugs (in this case streptomycin,
isonazid, rifampicin, and ampicillin) as before. The average
pfu/ml versus time (hours) was measured in this assay. An
increase in phage numbers from time point 0 to time point 4 h
indicates that M. smegmatis mc2 155 is resistant to the drug. If
the phage numbers (pfu/ml) remain static then M. smegmatis
mc2 155 is sensitive to the drug under investigation.

Evaluation of the efficacy of the mycobacteriophage‑based
drug‑susceptibility assay by undertaking a blinded study
To rule out the chance of bias, a blinded study was conducted.
At the end of the blinded study, the identity of each drug was
confirmed. The bars indicate drugs to which M. smegmatis
mc2 155 is sensitive as phage numbers remain static from
time 0 to time 4 h. The bars which increase significantly
from time 0 h to time 4 h are drugs to which M. smegmatis
mc2 155 are resistant to as outlined in Figure 6. The identity
of the A was confirmed as isonazid (P = 0.016), B was

Figure 5: Drug‑susceptibility profiles of four drugs (erythromycin,
amoxicillin, pyranzaimide and ethambutol) using changes in average
pfu/ml of the mycobacteriophage TM4 versus time (hours T0–T2), utilizing
optimized conditions established previously
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phase within 48 h) and its nonpathogenic nature (i.e., model
organism). The rationale for utilizing mycobacteriophages in
this study is that they are widely applicable, cheap to propagate,
and have a rapid replication rate.

Figure 6: Blinded study to determine the resistance profiles of eight drugs
utilized above using the mycobacteriophage TM4 based on the changes
in average PFU/ml versus time (hours T0–T2), utilizing the optimized
conditions established previously

confirmed as rifampicin (P = 0.012), C was confirmed
as pyranzaimide (P = 0.019), and D was confirmed
as ethambutol (P = 0.011). M. smegmatis mc 2 155 is,
in fact, sensitive to these four drugs as outlined in the
literature,[10,11] thereby validating this method. The identity
of E was confirmed as ampicillin (P = 0.049), F was
confirmed as erythromycin (P = 0.041), G was confirmed
as amoxicillin (P = 0.044), and H was confirmed as
streptomycin (P = 0.047). Various studies have outlined that
M. smegmatis mc2 155 is resistant to these four drugs.[12,13]
Universally, the data obtained in relation to the drug
susceptibilities is statistically significant as P < 0.05 at a
confidence interval of 95% were obtained as outlined above.

Discussion
Over the past years, the use and misuse of antimicrobials has
increased the numbers and types of resistant organisms including
mycobacterial species. As a large majority of mycobacterial
species have relatively slow‑growth rates, it would be of
importance to detect these resistant strains within an adequate
period of time to provide appropriate treatment options.
Advanced drug‑susceptibility assays have been developed
within recent years such as the BACTEC TB480 method and
the MGIT method particularly in hospital settings, however
these assays can take days or weeks to generate results.[14,15]
Based on this knowledge, it would be of interest to be able
to construct an assay which can identify drug susceptibilities
within a shorter period, to expedite clinical treatment. The major
applications of such a rapid viability assay would include (1)
determining drug sensitivities of clinical mycobacterial isolates
and (2) identifying novel antimycobacterial drugs using
high‑throughput screening (HTS).
The assay was a preliminary study to provide proof of concept
that mycobacteriophages can be used to detect drug resistance
or sensitivity using a fast‑growing mycobacterial strain before
the assay can be translated to more complex mycobacterial
species. For this purpose, M. smegmatis mc2 155 was employed
in this study as it is a very useful surrogate for the research
of other species in the genus mycobacteria (slow growers) in
laboratories, due to its rapid replication (reaches stationary
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To assess drug susceptibilities of M. smegmatis mc2 155, eight
drugs typically used to treat mycobacterial infections were
chosen, four drugs, in which M. smegmatis mc2 155 has been
shown to be resistant and four drugs, in which M. smegmatis
mc2 155 has exhibited sensitivity. Before conducting the assay,
optimization steps had to be performed. The length of time the
drug, bacteria, and mycobacteriophage were in contact was
an important optimization step, as the less time required for
contact implied that the drug‑susceptibility results could be
obtained rapidly, which was a main focus of the study.
The following completion of the optimization steps and the
assay, a blinded study was conducted, to authenticate that the
results generated were not affected by bias. The blinded study
was another crucial part of the assay to provide proof of concept
that the assay can work efficiently. The blinded study had the
ability to validate that the utilization of mycobacteriophage
has the potential to identify drug‑susceptible isolates within a
shorter period compared to the BACTEC and MGIT methods.
In comparison to the cost of the BACTEC 460TB method (One
US dollar and three dimes) and MGIT method (One US dollar
and 2 dimes), drug susceptibilities can be detected within 1½
days (albeit for a rapid mycobacterial host) with an average
cost of approximately one euro and fifteen cent.[16,17]
Although initially promising, there is uncertainty about the
applicability of this assay to other mycobacterial species.
Incubation periods for slow‑growing mycobacterial species are
approximately 4–16 weeks, in comparison to a fast‑growing
mycobacterial host (in this case M. smegmatis mc2 155) which
requires an incubation period of 24–48 h. Future work will
focus on developing this assay to generate rapid results with
slow‑growing pathogenic Mycobacterial strains.
As the assay has demonstrated the ability of one
mycobacteriophage strain to identify drug‑susceptible/resistant
isolates against M. smegmatis mc2 155 it may be possible to
utilize this assay as an HTS tool for novel anti‑Mycobacterial
drugs based plaque numbers. The assay would also increase
the speed in which novel drugs or compounds are detected.
As antibiotic resistance is becoming a major global threat, the
development of novel drug compounds is of major importance.

Conclusion
Rapidly, emerging resistant bacteria place substantial health
and economic burden globally. Till date, there has been a
lack of research in the development of a novel method to
identify drug susceptibilities for mycobacteria. Established
drug‑susceptibility methods such as the MIC assay, Kirby
Baeur method are currently in use but are extremely
time‑consuming (8–15 days). To reduce the time involved, it is
quite evident that progress is required in this area of research.
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The utilization of mycobacteriophage as a novel indicator
of drug susceptibilities has been explored in this study. The
addition of mycobacteriophage to the study has a significant
reduction in the time required to obtain drug‑susceptibility
results for M. smegmatis mc2 155. As mycobacteria are a
slow‑growing bacterial species, this assay may, therefore, have
the potential to be applied to other slow‑growing bacterial
species. The cost of performing the assay is relatively cheap
allowing more samples to be analyzed in one test. This assay,
therefore, has multiple applications such as the potential
identification of slow‑growing bacteria drug‑susceptible
isolates, its use in HTS to identify novel compounds and drugs
and the speed and cost involved in identifying drug‑susceptible
isolates.
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